Future Virology. 2013;8(1):1-2. During the global 2002/2003 SARS pandemic, many foundations, pharmaceutical companies and governments provided abundant funds to support the development of anti-SARS ...

Much research to elucidate potential antigens, routes of vaccination, and methods for the design of SARS vaccines has been completed. Immunogenicity has been widely demonstrated, but identification of ...

Viral mimic systems and other tech platforms could enable local testing of vaccine candidates and antiviral therapies. This is important in the context of low-resourced health settings, Africa's focus ...

When the SARS coronavirus spread around the world in 2003, it resulted in more than 8,000 cases, nearly 800 deaths, and $50 billion in economic damage. During this time, understandably, there was ...

The story of the emergence, spread, and control of severe acute respiratory syndrome (SARS) is the latest, most vivid episode of a microbial threat in our highly connected world. The SARS epidemic of ...